Multiple Sclerosis Journal - October 2017 - 1505

MM Voortman, T Stojakovic et al.
17. Khalil M, Enzinger C, Langkammer C, et al.
Quantitative assessment of brain iron by R(2)*
relaxometry in patients with clinically isolated
syndrome and relapsing-remitting multiple sclerosis.
Mult Scler 2009; 15(9): 1048-1054.
18. Teunissen CE, Petzold A, Bennett JL, et al. A
consensus protocol for the standardization of
cerebrospinal fluid collection and biobanking.
Neurology 2009; 73: 1914-1922.
19. Felgenhauer K, Schliep G and Rapic N. Evaluation
of the blood-CSF barrier by protein gradients and the
humoral immune response within the central nervous
system. J Neurol Sci 1976; 30: 113-128.
20. Link H and Tibbling G. Principles of albumin and
IgG analyses in neurological disorders. III. Evaluation
of IgG synthesis within the central nervous system
in multiple sclerosis. Scand J Clin Lab Invest 1977;
37(5): 397-401.
21. Andersson M, Alvarez-Cermeño J, Bernardi G, et al.
Cerebrospinal fluid in the diagnosis of multiple
sclerosis: A consensus report. J Neurol Neurosurg
Psychiatry 1994; 57: 897-902.
22. Khalil M, Langkammer C, Gattringer T, et al.
Dynamics of brain iron levels in multiple sclerosis.
Neurology 2015; 84: 2396-2402.
23. Khalil M, Langkammer C, Ropele S, et al.
Determinants of brain iron in multiple sclerosis: A
quantitative 3T MRI study. Neurology 2011; 77(18):
1691-1697.
24. Plummer DL. DispImage: A display and analysis
tool for medical images. Rev Neuroradiol 1992; 5(4):
489-495.
25. Smith S, Jenkinson M, Woolrich M, et al. Advances
in functional and structural MR image analysis and
implementation as FSL. Neuroimage 2004; 23(Suppl.
1): S208-S219.
26. Rudick RA, Cookfair DL, Simonian NA, et al.
Cerebrospinal fluid abnormalities in a phase III trial

journals.sagepub.com/home/msj

of Avonex® IFNβ-1a for relapsing multiple sclerosis.
J Neuroimmunol 1999; 93: 8-14.
27. Pröbstel A-K, Sanderson N and Derfuss T. B cells
and autoantibodies in multiple sclerosis. Int J Mol Sci
2015; 16(7): 16576-16592.
28. Freedman M, Thompson E, Deisenhammer F, et al.
Recommended standard of cerebrospinal fluid
analysis in the diagnosis of multiple sclerosis. Arch
Neurol 2005; 62(6): 865-870.
29. Nakano T, Matsui M, Inoue I, et al. Free
immunoglobulin light chain: Its biology and implications
in diseases. Clin Chim Acta 2011; 412(11-12): 843-849.
30. Joseph FG, Hirst CL, Pickersgill TP, et al. CSF
oligoclonal band status informs prognosis in multiple
sclerosis: A case control study of 100 patients. J
Neurol Neurosurg Psychiatry 2009; 80(3): 292-296.
31. Annunziata P, Giorgio A, De Santi L, et al. Absence
of cerebrospinal fluid oligoclonal bands is associated
with delayed disability progression in relapsingremitting MS patients treated with interferon-β. J
Neurol Sci 2006; 244(1-2): 97-102.
32. Dispenzieri A, Kyle R, Merlini G, et al. International
Myeloma Working Group guidelines for serum-free
light chain analysis in multiple myeloma and related
disorders. Leukemia 2009; 23: 215-224.
33. Han X, Wang J, Zhang N, et al. The prognostic utility
and the association of serum light chains (free and
total) and absolute lymphocyte count in patients with
newly diagnosed diffuse large B-cell lymphoma. Leuk
Res 2014; 38(11): 1291-1298.
34. Rudick R, Medendorp S, Namey M, et al. Multiple
sclerosis progression in a natural history study:
Predictive value of cerebrospinal fluid free kappa
light chains. Mult Scler 1995; 1: 150-155.
35. Rinker JR, Trinkaus K and Cross AH. Elevated
CSF free kappa light chains correlate with disability
prognosis in multiple sclerosis. Neurology 2006;
67(7): 1288-1290.

Visit SAGE journals online
journals.sagepub.com/
home/msj

SAGE journals

1505

http://journals.sagepub.com/home/msj http://journals.sagepub.com/home/msj https://journals.sagepub.com/home/msj

Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017